"Syöpäkeskus vastaa syövän onkologisesta hoidosta koko HUS-alueella. Helsingin ja Uudenmaan lisäksi klinikalla hoidetaan myös muualta Suomesta saapuvia, erikoisosaamista vaativia potilaita. Tutkimukset, hoitosuunnitelmat sekä sädehoito toteutetaan pääosin Meilahden klinikalla, leikkaushoidot puolestaan eri kirurgian yksiköissä. Kahvila sijaitsee 1. kerroksessa. Kahvila on suljettu toistaiseksi. Sisääntulokerroksessa (0. kerros) on kahviautomaatti."

During the past decade, Department of Hematology Helsinki University Hospital Comprehensive Cancer Center conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Department of Hematology Helsinki University Hospital Comprehensive Cancer Center" #1 collaborator was "AstraZeneca" with 1 trials as a collaborator, "ICON Clinical Research" with 1 trials as a collaborator and "Roche Pharma AG" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Department of Hematology Helsinki University Hospital Comprehensive Cancer Center" are "DLBCL" (1 trials), "Diffuse Large B Cell Lymphoma" (1 trials), "Follicular Lymphoma" (1 trials), "MCL" (1 trials) and "Malignant Lymphoma" (1 trials). Many other conditions were trialed in "Department of Hematology Helsinki University Hospital Comprehensive Cancer Center" in a lesser frequency.

Most popular intervention types in "Department of Hematology Helsinki University Hospital Comprehensive Cancer Center" are "Drug" (5 trials). Other intervention types were less common.

The name of intervention was led by "Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma" (1 trials), "Betalutin" (1 trials), "PREBEN" (1 trials), "R-mini-CHOP" (1 trials) and "R-pola-mini-CHP" (1 trials). Other intervention names were less common.

The vast majority of trials in "Department of Hematology Helsinki University Hospital Comprehensive Cancer Center" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Department of Hematology Helsinki University Hospital Comprehensive Cancer Center". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Department of Hematology Helsinki University Hospital Comprehensive Cancer Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Department of Hematology Helsinki University Hospital Comprehensive Cancer Center, 3 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".